RE:RE:New Press Release - Shareholder Alert: Ademi LLP investigates whether Aeterna Zentaris Inc.'s transaction with Ceapro was Fair to ShareholdersIt could have been written by an automated Ai program just fishing for business. The US has a lot of these investigation news releases flood a major even when the stock drops. AEZS has fallen from ~C$14 to ~C$10 as the warrants are converted. Now how many of the people who pushed the stock up to get the warrants may sell the warrants or maybe all of it. CZO's last financials were also underwhelming.This company is still a mystery too.
AEZS is still every much a mystery until we see a plan, data, and key events. People are worried about the burn rate and how quickly cash will run out. Will it run out before AEZS can hit material valuation catalysts and will it be forces to dilute again? We need a solid plan. The diagnostic data is due in Q3 and then we could see a deal. How much cash? We've never seen any preclinical data for the avenanthramide pill. It might not be for some time that we see the first safety/tolerability, and preliminary efficacy data and have a better basis for speculation. There's data ahead of AEZS's pipeline programs and talks with regulators concerning the path forward. How much work to do before this gets to human trials and proving itself in humans? Do we have the cash? PGX hasn't cleared the 50L hurdle and then needs to clear the 100L. Let's hope it goes smoothly. A licensing deal can also be key validation.
Two key steps are the diagnostic data, regulatory filings for approval, and a deal with upfront cash. We need a plan for the new company with prioritized assets. Maybe we see that on or before the AGM on July 16, 2024. Until then lets see if the stock falls and we get more of these lawsuit announcements. An analyst report could help. The first avenanthramide pill data could be imminent but we may need more.